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Abstract 
 
Calcidiol, the major circulating metabolite of vitamin D, supports induction of pleiotropic 
antimicrobial responses in vitro. Vitamin D supplementation elevates circulating calcidiol 
concentrations, and thus has a potential role in the prevention and treatment of infection. 
The immunomodulatory effects of administering vitamin D to humans with an infectious 
disease have not previously been reported. In order to characterise these effects, we 
conducted a detailed longitudinal study of circulating and antigen-stimulated immune 
responses in ninety-five patients receiving antimicrobial therapy for pulmonary tuberculosis 
who were randomised to receive adjunctive high-dose vitamin D or placebo in a clinical trial, 
and who fulfilled criteria for per-protocol analysis. Vitamin D supplementation accelerated 
sputum smear conversion and enhanced treatment-induced resolution of lymphopaenia, 
monocytosis, hypercytokinaemia and hyperchemokinaemia. Administration of vitamin D also 
suppressed antigen-stimulated proinflammatory cytokine responses, but attenuated the 
suppressive effect of antimicrobial therapy on antigen-stimulated secretion of interleukin-4, 
CC chemokine ligand 5 and interferon-α. We demonstrate a previously unappreciated role 
for vitamin D supplementation in accelerating resolution of inflammatory responses during 
tuberculosis treatment. Our findings suggest a potential role for adjunctive vitamin D 
supplementation in the treatment of pulmonary infections to accelerate resolution of 
inflammatory responses associated with increased risk of mortality.  
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Introduction 
 
Despite the widespread availability of antimicrobials, bacterial respiratory infections remain a 
major global cause of death(1). Mortality is associated with infection with antibiotic-resistant 
organisms(2, 3) and with failure to resolve immunopathological inflammatory responses(4-6). 
Immunomodulatory agents that augment antimicrobial immune responses and accelerate 
resolution of pulmonary inflammation could be used as adjuncts to antimicrobial therapy to 
improve treatment outcomes(7). 
 
Calcitriol, the active metabolite of vitamin D, induces innate antimicrobial responses and 
suppresses pro-inflammatory cytokine responses in vitro(8). Its antimicrobial activity is 
mediated via induction of reactive nitrogen intermediates, reactive oxygen intermediates, 
antimicrobial peptides and autophagy(9). Calcitriol also modulates adaptive responses, both 
indirectly (by suppression of MHC class II expression and IL-12 secretion by antigen-
presenting cells) and directly (by suppressing secretion of interferon-γ (IFN-γ) and 
interleukin-2 (IL-2) from CD4+ T helper type 1 (Th1) cells(10)). Calcitriol is synthesised by 
the vitamin D 1-alpha hydroxylase enzyme, whose expression is upregulated in leucocytes 
and pulmonary epithelium following ligation of toll-like receptors by pathogen-associated 
ligands(11, 12). Extra-renal generation of calcitriol is dependent on the availability of its 
precursor calcidiol, the major circulating vitamin D metabolite that supports induction of 
antimicrobial responses in vitro(11, 13) and whose concentrations are often low in patients 
with pulmonary infection(14-16). Vitamin D supplementation elevates circulating calcidiol 
concentrations, and may therefore enhance response to antimicrobial therapy for respiratory 
infections. However, the effects of in vivo vitamin D supplementation on immune responses 
in humans with an infectious disease have not previously been described. 
 
Vitamin D was used to treat tuberculosis in the pre-antibiotic era(17), and vitamin D 
supplementation has been shown to enhance healthy tuberculosis contacts’ immunity to 
mycobacteria(18). These observations prompted us to conduct a randomised controlled trial 
evaluating the influence of adjunctive high-dose vitamin D on time to bacterial clearance in 
patients receiving antimicrobial therapy for smear-positive pulmonary tuberculosis(19). We 
now present results of a detailed analysis of longitudinal changes in the immune response in 
trial participants during the 8-week course of intensive-phase antituberculous therapy. 
Initially we describe the effects of antituberculous therapy alone on circulating and antigen-
stimulated immune responses, using samples from patients randomised to the placebo arm 
of the trial. Subsequently we proceed to characterise the effects of vitamin D 
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supplementation using samples from those randomised to the intervention arm of the study, 
showing that administration of adjunctive vitamin D exerts pleiotropic immunomodulatory 
effects in patients with pulmonary tuberculosis. 
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Results 
 
Effect of antimicrobials on circulating responses 
 
Determination of the immunomodulatory effects of vitamin D supplementation necessitated 
an initial, comprehensive characterisation of the changes in immune responses induced by 
antituberculous therapy alone. To this end, 42 soluble factors and 14 haematological 
parameters detailed in Materials and Methods were measured in samples of serum, plasma 
and whole blood taken from 51 patients randomised to the placebo arm of the trial at 0, 2, 4, 
6 and 8 weeks of treatment (for trial profile see Figure S1; for baseline characteristics, see 
Table S1). Parameters were selected on the basis that they played a role in host defence 
against Mycobacterium tuberculosis (MTB)(20) and / or that they were biomarkers of 
treatment response (21). Median serum concentrations of seven soluble factors (IL-2, IL-5, 
IL-13, IL-17, tumour necrosis factor (TNF), basic fibroblast growth factor (FGF-β) and matrix 
metalloproteinase-7 (MMP-7) were below the limit of detection (LOD) at baseline, and these 
were excluded from statistical analyses. The remaining 49 parameters were assessed using 
principal component analysis (PCA), a well-established mathematical technique for reducing 
the dimensionality of complex data sets by transformation of data to a 3-dimensional 
coordinate system (22). The resultant 3-dimensional PCA plot (Video S1A) showed a 
gradient of samples from week 0 to 8 along principal component 1. Baseline samples 
occupied more space than follow-up samples (13/51 vs. 30/49 data points with Euclidean 
distance <5 at baseline vs. 8 weeks respectively, p=0.003), indicating that patients had a 
relatively heterogeneous immunological profile at baseline that became more homogenous 
as treatment progressed. 
 
Rank regression analysis (23) was applied to PCA-transformed data in order to identify 
parameters whose concentration changed significantly over time. Table 1 presents details of 
the 42 circulating immunological parameters so identified. Of the haematological parameters 
investigated, platelet count, neutrophil count and monocyte count decreased during the 
course of treatment (p≤0.0018), while lymphocyte count and eosinophil count both increased 
(p≤0.0019). Increases were also seen in haemoglobin concentration and red blood cell 
parameters (p≤0.015), reflecting resolution of microcytic anaemia as treatment progressed. 
Decreases in erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) 
(p<1.24x10-12) and an increase in serum albumin concentration (p=5.17x10-21) were also 
seen, indicating resolution of the acute phase response. These changes were accompanied 
by a decrease in circulating concentrations of all cytokines, chemokines, antimicrobial 
6 
 
peptides (AMP), MMP and angiogenic factors identified (p≤0.0240) except for CCL2 and 
MMP-2, whose concentration increased during the course of treatment (p≤0.0035). 
 
To investigate the relationship between changes in cell counts and circulating concentrations 
of inflammatory mediators observed during treatment, network PCA was applied to the 
parameters listed in Table 1. Seven distinct clusters were identified (Video S2A). For 
parameters whose values fell during treatment, the tightest cluster incorporated three MMP 
(MMP-1, MMP-8 and MMP-9) with three AMP (human neutrophil peptides [HNP] 1-3, 
neutrophil gelatinase-associated lipocalin [NGAL] and cathelicidin [LL-37]); this cluster was 
close to neutrophils, CXCL8 and PGE2. Neutrophils were linked to monocytes and CRP, 
which in turn was linked to IL-6 and ESR. Platelet count and CCL5 formed a distinct 
grouping, while the other IFN-γ-stimulated chemokines CXCL9 and CXCL10 were linked to 
each other and to IFN-γ, which was linked to IL-6. The angiogenic factors epidermal growth 
factor (EGF) hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) 
were linked to each other and IL-7, IL-10, IL-15 and soluble IL-2 receptor (IL-2R). For 
parameters increasing during treatment, one network incorporated red blood cell 
parameters, albumin and MMP-2, and another linked lymphocyte and eosinophil count. 
 
Effect of antimicrobials on antigen-stimulated responses 
 
Whole blood samples taken from 28 patients randomised to the placebo arm of the trial were 
stimulated ex vivo with a panel of mycobacterial antigens, and the concentration of IFN-γ in 
supernatants of baseline samples was compared between stimuli. Of the MTB-specific 
antigens tested, recombinant early secreted antigenic target, 6 kDa, (rESAT-6) and 
recombinant culture filtrate protein, 10 kDa (rCFP-10) induced the greatest IFN-γ responses 
(Figure S2). We therefore proceeded to assay concentrations of 39 soluble factors listed in 
Materials and Methods in supernatants of whole blood stimulated with these two antigens at 
0, 2, 4, 6 and 8 weeks of treatment. Median concentrations of six soluble factors (IL-2, IL-5, 
IL-13, EGF, FGF-β and MMP-7) were below the LOD in these samples, and these 
parameters were therefore excluded from statistical analyses. The remaining 33 parameters 
were analysed by PCA and rank regression. The resultant PCA plots for rESAT-6- and 
rCFP-10-stimulated responses (Video S1B-C) were similar to each other: as before, samples 
converged from a loosely clustered pattern towards a more tightly clustered pattern as 
treatment progressed. Twenty-seven antigen-stimulated parameters contributed to the 
pattern of response to antituberculous therapy (Table 1). All analytes whose concentration 
changed significantly during the course of intensive phase antituberculous therapy showed a 
decrease in secretion over time. Of note, IFN-γ was among the analytes whose antigen-
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stimulated concentration did not change significantly during the course of antituberculous 
therapy, even when corrected for changes in lymphocyte count (Figure S3). 
 
In order to determine whether changes in antigen-stimulated immune responses 
corresponded to changes in whole blood cellular composition during antituberculous therapy, 
network PCA was applied to the antigen-stimulated analytes listed in Table 1 together with 
cell count data obtained for the relevant samples prior to antigenic stimulation. Similar PCA 
networks were identified for rCFP-10- and rESAT-6-stimulated responses (Video S2B-C). 
Platelets, CCL5, IL-4, granulocyte-colony stimulating factor (G-CSF) and CCL11 were 
connected in both plots, replicating the platelet-CCL5 connection observed in the analysis of 
circulating parameters (Video S2A). Neutrophils occupied a similar space to neutrophil 
granule-associated proteins MMP-9 and NGAL. IL-7 clustered with another angiogenic 
factor, VEGF, and Th1 cytokines. Lymphocytes were not connected directly to any cytokines 
stimulated by rESAT-6 or rCFP-10. 
 
Effects of vitamin D on circulating responses 
 
We have previously reported results of the intention-to-treat analysis of study data, indicating 
that administration of adjunctive vitamin D was associated with a trend towards faster 
sputum culture conversion (p=0.14)(19). We repeated this analysis in the subgroup of 95 
participants fulfilling per-protocol analysis criteria, adjusting for factors previously shown to 
influence time to sputum conversion in this dataset (age, ethnicity, baseline sputum smear, 
neutrophil count, and presence or absence of cavitation on baseline chest radiograph). 
Median time to sputum culture conversion in this subset of patients was 35.0 days in the 
intervention group and 46.5 days in the control group (hazard ratio 1.27, 95% CI 0.76 to 
2.13, p=0.36), while median time to sputum smear conversion in the intervention arm was 
significantly shorter than that in the control arm (23 vs. 36 days; hazard ratio 1.69, 95% CI 
1.02 to 2.79, p=0.04; Figure 1A). 
 
In order to determine whether the effect of vitamin D on time to sputum clearance in the per-
protocol sub-group was associated with immunomodulatory activity, we compared the effect 
of antituberculous therapy on the circulating immunological parameters investigated above in 
51 patients randomised to the placebo arm of the trial vs. 44 patients randomised to receive 
adjunctive vitamin D using  PCA and rank regression on the interaction term ‘treatment 
duration*allocation’. The PCA plot is shown in Video S3A. The seventeen circulating 
parameters identified as being significantly affected by vitamin D are detailed in Table 2. All 
of these were also significantly affected by intensive phase antituberculous therapy: in every 
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case, vitamin D accelerated the effect of antituberculous therapy. The analyte most affected 
by vitamin D was the chemokine CXCL9, whose serum concentration decreased significantly 
faster in patients randomised to receive vitamin D vs. placebo (p=5.92 x10-12). Serum 
concentrations of three other chemokines (CXCL10, CCL3 and CCL5) also fell more rapidly 
in patients randomised to vitamin D vs. placebo (p≤0.0164), as did IFN-γ (p=0.0012). 
Monocyte counts fell more rapidly (p=3.54 x10-4) and lymphocyte counts rose more rapidly 
(p=0.0365) among patients receiving vitamin D. Neutrophil counts were not significantly 
affected by allocation, but plasma concentrations of neutrophil-associated AMP (LL-37, 
HNP1-3 and NGAL) and MMP-9 fell more quickly in patients receiving adjunctive vitamin D 
(p≤0.0111). Administration of vitamin D also induced a more rapid drop in ESR and serum 
CRP concentration (p≤0.0027), indicating accelerated resolution of the acute phase 
response. 
 
Network PCA indicated that the accelerated fall in monocyte count in patients receiving 
vitamin D was linked to a rise in lymphocyte count and a decrease in ESR and serum CRP 
concentration (Figure S4A). The IFN-γ-inducible chemokines CXCL9 and CXCL10 were 
linked to IFN-γ, IL-2R, IL-10 and CCL3. NGAL, HNP1-3 and MMP-9 formed another cluster, 
which was linked to LL-37 and PGE2. The kinetics of change in a representative group of 
circulating immunological parameters over the course of intensive phase therapy in vitamin 
D vs. placebo arms are presented in Figure 1B-H. 
  
We have previously reported that the effect of vitamin D on time to sputum culture 
conversion is modified by the TaqI genotype of the vitamin D receptor (VDR), such that 
vitamin D hastens sputum culture conversion in patients with the tt genotype, but not in 
those with Tt or TT genotypes  (Figure S5A-C)(19). To investigate whether the effects of 
vitamin D on circulating immune responses were also restricted to patients with this 
genotype, we stratified analysis of the effects of vitamin D on 8-week values of analytes 
listed in Table 2 according to TaqI genotype. In patients with the TT genotype, vitamin D 
supplementation significantly reduced 8-week circulating concentrations of CRP, CXCL9, 
CXCL10, NGAL and LL-37, while in those with the Tt genotype, vitamin D significantly 
reduced 8-week circulating concentrations of CXCL9 and IL-10 (Figure S5D-I; p≤0.045). 
These analyses indicate that immunomodulatory effects of vitamin D are not restricted to 
individuals with the tt genotype of the TaqI VDR polymorphism. 
 
Effects of vitamin D on antigen-stimulated responses 
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We next investigated the effect of vitamin D supplementation on antigen-stimulated 
responses using  PCA and interaction analysis on 34 analytes detailed above for 19 patients 
allocated to vitamin D vs. 28 patients allocated to placebo. The PCA plots generated for 
responses to rESAT-6 and rCFP-10 were similar to each other, and samples from patients 
allocated to vitamin D vs. placebo were clearly separated (Video S3B-C). Vitamin D 
supplementation influenced supernatant concentrations of seven analytes in both rESAT-6- 
and rCFP-10-stimulated whole blood (Table 2); notably, IFN-γ was not among them (Figure 
S3). Vitamin D enhanced the suppressive effect of antimicrobial therapy on secretion of IL-1 
receptor antagonist (IL-1RA), IL-6, IL-12 and TNF (p≤0.0437) and attenuated treatment-
induced reductions in secretion of IL-4, CCL5 and IFN-α (p≤0.0323). Network PCA showed 
that IL-12, TNF and IL-1RA were linked, while IL-6 was connected to monocytes directly or 
via VEGF, and CCL5 and IL-4 were tightly clustered and linked to IFN-α for both antigens 
(Figure S4B-C). Vitamin D significantly reduced antigen-stimulated secretion of IL-12, TNF, 
IL-1RA, IL-6, CXCL10, CCL3, CCL4 and VEGF (Figure 1I-L) and enhanced CCL5, CCL11, 
IL-4 and IFN-α secretion.  
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Discussion 
 
Our study represents the most detailed characterisation of the effects of antituberculous 
therapy on the immune response conducted to date, and the first clinical investigation into 
the immunomodulatory actions of in vivo vitamin D supplementation during treatment of an 
infectious disease. In patients taking antimicrobial therapy for smear-positive pulmonary 
tuberculosis, adjunctive vitamin D accelerated sputum smear conversion, augmented 
treatment-induced increases in lymphocyte count and enhanced the suppressive effect of 
treatment on monocyte count, inflammatory markers and circulating concentrations of 
chemokines, antimicrobial peptides and MMP-9. Administration of vitamin D also enhanced 
treatment-induced suppression of antigen-stimulated Th1 cytokine responses, but 
attenuated treatment-induced suppression of antigen-stimulated IL-4, CCL5 and IFN-α 
secretion. 
 
Among 51 patients randomised to receive antituberculous therapy plus placebo, we 
observed an increase in circulating lymphocyte count and a reduction in circulating 
neutrophil counts, monocyte counts and concentrations of IFN-inducible parameters 
following initiation of antituberculous therapy, consistent with previous reports (24-26). These 
changes were associated with decreases in circulating concentrations of lymphocyte 
chemoattractants CXCL9 and CXCL10, and an increase in the monocyte chemoattractant 
CCL2; they may therefore reflect reduced recruitment of lymphocytes, and increased 
recruitment of monocytes, to the lung.  In keeping with this hypothesis, the proportion of 
macrophages in sputum of tuberculosis patients has been reported to increase as treatment 
progresses (27). Interestingly, increases in circulating lymphocyte count following initiation of 
antituberculous therapy were not associated with any change in antigen-stimulated 
production of IFN-γ as treatment progressed. By contrast, antigen-stimulated production of 
CCL5, IL-4, G-CSF, IFN-α and CXCL10 were greatly decreased over the course of 
intensive-phase therapy. Antigen-stimulated CXCL10 responses have been reported to be 
more sensitive than IFN-γ for the diagnosis of active tuberculosis(28), and these data 
suggest that this panel of analytes may also hold promise as antigen-stimulated biomarkers 
of treatment response. Resolution of thrombocytosis is another well recognised 
phenomenon associated with TB treatment(29), and network analysis revealed this to be 
linked to a decrease in circulating CCL5 and antigen-stimulated CCL5 and IL-4 among 
patients in our study. Although best known for their role in haemostasis, platelets are also 
recognised to secrete CCL5(30), which can enhance production of IL-4 by CD4+ T cells(31). 
The role of platelets in the antimycobacterial response warrants further investigation. 
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Having characterised the immune response to antituberculous therapy, we proceeded to 
investigate how this was affected by administration of adjunctive vitamin D. In contrast to 
studies investigating immunomodulatory actions of vitamin D supplementation in healthy 
people and in those with non-communicable diseases (32-35), we report pleiotropic 
immunomodulatory actions of vitamin D in tuberculosis patients. This difference may reflect 
the very high prevalence of profound deficiency at baseline among participants in our study; 
the relatively high dose of vitamin D administered; or the fact that MTB can upregulate 
expression of the vitamin D 1-alpha hydroxylase CYP27B1 to generate immunomodulatory 
concentrations of calcitriol at sites of infection(11). Among patients fulfilling criteria for per-
protocol analysis (n=96), vitamin D accelerated sputum smear conversion (p=0.04). This 
finding contrasts with results of our previously published intention-to-treat analysis (n=126), 
in which a trend towards faster conversion in vitamin D-supplemented patients did not attain 
statistical significance (19). This difference may reflect the superior compliance of 
participants included in the per-protocol analysis, which excluded patients who did not take a 
full course of study medication. Vitamin D also suppressed circulating concentrations of IFN-
γ and IFN-γ-inducible chemokines CXCL9 and CXCL10, the matrix metalloproteinase 
enzyme MMP-9 and antigen-stimulated Th1 responses. These in vivo findings are consistent 
with reported immunomodulatory actions of calcitriol in vitro (8, 36, 37). In contrast to these 
suppressive actions, vitamin D also attenuated treatment-induced falls in antigen-stimulated 
CCL5, IL-4 and IFNα. IL-4 has recently been reported to induce expression of CYP24A, the 
principal catabolic enzyme of both calcidiol and calcitriol(38); the increase in antigen-
stimulated IL-4 secretion observed in the intervention arm of the study may therefore 
represent part of a negative feedback loop via which calcitriol regulates its own 
concentration at the site of disease. The finding that administration of vitamin D enhanced 
antigen-stimulated IFN-α responses is of particular interest, given the pivotal role of type 1 
interferons in antiviral responses(39), and the clinical observation of a 6-fold reduction in 
upper respiratory tract infections among patients in the intervention arm of the trial(19). 
Modulation of antigen-stimulated responses by vitamin D supplementation may represent 
changes in numbers of circulating lymphocyte sub-populations and / or direct effects of 
vitamin D on lymphocyte function. More detailed characterisation of the effects of vitamin D 
supplementation on numbers and cytokine profiles of lymphocyte subsets is warranted.  
 
Although many of the immunomodulatory effects of in vivo vitamin D supplementation that 
we observed were in keeping with the in vitro actions of calcitriol, there were two exceptions: 
calcitriol has been reported to induce IL-10(36) and the antimicrobial peptides LL-37 and 
NGAL(40, 41) in vitro, but we found that in vivo vitamin D supplementation suppressed 
circulating concentrations of IL-10, LL-37 and NGAL. All three of these markers are 
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suppressed by antituberculous therapy alone (Table 1), and the fact their concentration fell 
more quickly among patients in the intervention arm of the study may arise as an indirect 
consequence of enhanced microbial killing in patients receiving vitamin D. Alternatively, this 
observation may represent a direct suppressive effect of vitamin D on release of these 
mediators into the circulation from neutrophil granules.  
 
Interestingly, and in contrast to the effects of vitamin D supplementation on sputum 
clearance that we have previously demonstrated (19), we found that immunomodulatory 
effects of vitamin D were observed in patients having the TT and Tt  genotypes of the TaqI 
vitamin D receptor polymorphism (the effects of vitamin D in patients with the tt genotype 
could not be determined, due to small numbers in this group). This observation suggests that 
if these responses can be augmented - by administering vitamin D at higher doses, for 
example - then tuberculosis patients might derive a clinical benefit from vitamin D 
supplementation irrespective of TaqI genotype. More broadly, the ability of vitamin D to 
accelerate resolution of potentially immunopathological inflammatory responses without 
compromising bacterial killing raises the possibility that supplementation might also have 
benefits in patients receiving antimicrobial therapy for pneumonia and sepsis, in whom 
failure to resolve hypercytokinaemia is associated with increased mortality(5, 6). 
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Materials and Methods 
 
Details of the trial protocol have previously been reported; participants were randomised to 
receive four fortnightly doses of 2.5 mg vitamin D3 vs. placebo in addition to standard 
antituberculous therapy(19). Antigen-stimulated whole blood assays were performed as 
previously described(42). Concentrations of IL-1β, IL-1RA, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, 
IL-10, IL-12 (p40/p70), IL-13, IL-15, IL-17, G-CSF, GM-CSF, IFN-α, IFN-γ, TNF, CXCL8, 
CXCL9, CXCL10, CCL2, CCL3, CCL4, CCL5, CCL11, EGF, FGF-β, HGF and VEGF were 
quantified using a human 30-plex bead immunoassay panel (Invitrogen, Camarillo, CA, 
USA). Serum CRP and albumin concentrations were assayed using an Architect ci8200 
analyser (Abbott Diagnostics, Chicago, IL, USA). Serum PGE2 concentration was analysed 
by high sensitivity competitive enzyme immunoassay (Assay Designs, Ann Arbour, MI, 
USA). Concentrations of LL-37, HNP1-3 and NGAL were analysed by ELISA (Hycult 
Biotechnology, Uden, The Netherlands). Concentrations of MMP-1, -2, -3, -7 and -8 were 
determine by Fluorokine MAP multianlalyte profiling (R&D systems); concentration of MMP-9 
was determined by DuoSet ELISA (R&D systems). Antigen-stimulated AMP and MMP 
concentrations were corrected by subtraction of unstimulated values. Full blood counts were 
performed using a LH750 haematology analyser (Beckman Coulter, Brea, CA, USA). ESR 
was measured by the Wintrobe method using a s2000 analyser (Desaga, Wiseloch, 
Germany). DNA extraction and genotyping were performed as previously described (19). 
 
PCA was conducted using Qlucore Omics Explorer 2.2 (Qlucore AB, Lund, Sweden). 
Analyte concentrations were log2 converted and normalised to the mean for each analyte 
with variance -1 to +1. PCA networks were created using 1 connection. Rank regression 
analysis was applied to PCA-transformed data to identify parameters whose concentration 
was affected by antituberculous therapy (by making within-patient comparison of samples at 
different timepoints among patients allocated to placebo) and vitamin D (by making between-
patient comparison of samples from patients allocated to placebo vs. vitamin D.) These 
analyses yielded t statistics (calculated as the regression co-efficient for each parameter 
divided by its standard deviation) representing the magnitude of difference in concentration 
of a given parameter between groups being compared, and p values, representing the 
probability that such differences could have arisen by chance alone. The effects of allocation 
on circulating immune responses at 8 weeks within genetically defined sub-groups were 
analysed using Mann-Whitney U tests. The effect of allocation on time to sputum clearance 
was analysed by Cox regression analysis, The effect of allocation on time to sputum 
clearance was analysed by Cox regression analysis, adjusting for age, ethnicity, baseline 
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sputum smear, neutrophil count, and presence or absence of cavitation on baseline chest 
radiograph as previously described (19). 
 
Further details of materials and methods are presented in Text S1. 
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Figure legends 
 
 
Figure 1. Kinetics of circulating and antigen-stimulated immune responses during the 
course of antituberculous therapy in the presence vs. the absence of adjunctive 
vitamin D. Vitamin D accelerated sputum smear conversion in patients fulfilling per-protocol 
analysis criteria (A). Monocyte counts fell more quickly (B) and lymphocyte counts rose more 
quickly (C) among patients in the intervention arm of the trial. Vitamin D also accelerated 
treatment-induced decreases in erythrocyte sedimentation rate (ESR, D), circulating 
concentrations of CXCL9 (E), CXCL10 (F), MMP-9 (G) and LL-37 (H) and rCFP-10-
stimulated supernatant concentrations of IL-1RA (I), IL-6 (J), IL-12p40/p70 (K) and TNF (L). 
Means ± SEM at 0, 2, 4, 6 and 8 weeks of treatment are presented. Dotted lines, placebo 
arm; solid lines, vitamin D arm. 
 
 
Table legends 
 
Table 1. Influence of intensive-phase antituberculous therapy on circulating and 
antigen-stimulated immune responses in adults with smear-positive pulmonary 
tuberculosis 
 
Table 2. Influence of adjunctive vitamin D supplementation on circulating and antigen-
stimulated immune responses to intensive-phase antituberculous therapy 
